Retrophin's (RTRX) Head of R&D to Resign

October 6, 2016 4:33 PM EDT
Get Alerts RTRX Hot Sheet
Trade RTRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Retrophin, Inc. (Nasdaq: RTRX) announced Alvin Shih, M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016 and has agreed to serve as a consultant to Retrophin thereafter. The Company has initiated a search for a permanent successor. In the interim, chief executive officer Stephen Aselage will assume responsibility of the research and development organization.

“On behalf of the board and all our employees, I want to thank Alvin for his tremendous contributions to the rapid progression of our pipeline,” said Mr. Aselage. “Alvin is leaving us in a strong position to continue the advancement of sparsentan and RE-024; we wish him success in his new role.”

“While I am sad to leave Retrophin, I’m incredibly proud of the progress we have made towards delivering new therapies for rare disease patients,” said Dr. Shih. “I look forward to contributing to Retrophin’s future success as an external advisor.”

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Changes, Management Comments

Add Your Comment